Latest news with #DiversityActionPlan
Japan Times
05-04-2025
- Health
- Japan Times
As U.S. ditches diversity in clinical trials, all eyes on Europe
The United States once led the world in running clinical trials that aimed to look like the nation at large. Now it is dumping equality goals and slashing health research, so experts are looking to Europe and Britain to plug the diversity gap. Racial health inequality manifests in many ways — be it discriminatory treatment or higher death rates — but one glaring disparity kicks in at the get-go with the testing of all drugs, medical devices and treatments pre-launch. Studies show that ethnic minorities are far less likely to volunteer for such trials, a fact that health experts put down to mistrust of the health system, fear and misinformation. So when the pandemic showed that Black, Asian, Hispanic and other minority communities were worse hit by COVID-19 than white populations, governments, researchers and pharmaceutical firms all committed to greater diversity in future clinical trials. Recruiting more volunteers from different genders, sex, ages and ethnic groups is key to treating diseases more effectively and addressing disparities, health experts say. The United States was the first country to require companies to test medicines and devices in diverse populations when it brought in draft guidance in 2022, due to be finalized this year. "Diversity in clinical trials is not about an ideological position. It's about scientific accuracy and medical progress," said Joshua Sharfstein, a former top official at the U.S. regulatory body the Food and Drug Administration (FDA). But that progress now hangs in limbo as U.S. President Donald Trump's administration guts staff and funding from health departments, and scrubs diversity, equity and inclusion (DEI) policies from federal agencies. Demonstrators hold up signs while protesting outside the Center for Disease Control, in Atlanta, after the Trump administration began mass layoffs this month. | reuters The FDA's Diversity Action Plan draft guidance was among several U.S. government webpages removed in January due to "gender ideology" before a court order reinstated it. Researchers and health campaigners say it is unclear whether the United States will now implement the diversity guidance, as mandated by the 2022 Food and Drug Omnibus Reform Act. The FDA and the U.S. Department of Health and Human Services, which oversees the agency, did not immediately respond to requests for comment. The government on Tuesday began cutting 10,000 jobs at public health agency the Centers for Disease Control and Prevention, the FDA, and the National Institutes of Health, the leading funder of global medical research. "It's a very chaotic situation and one hopes for the best and one fears for the worst," said physician Robert Steinbrook, director of health research at U.S. advocacy group Public Citizen. "If the FDA were to abandon the scientific progress that has been made because of 'gender ideology' or other concepts which are quite ambiguous... it would be a big step backwards," he told the Thomson Reuters Foundation. Samantha Artiga, director of racial equity at U.S. health policy group KFF, said positive post-COVID initiatives could lose momentum under Trump. "We're likely to continue to see under-representation of groups in trials, particularly people of colour and women and other historically under-served groups," she said. A 2022 Lancet paper analyzing 20 years of studies showed that less than half of all U.S.-based trials included race and ethnicity data. Despite Black patients representing 21% of COVID-19 deaths, they made up only 3% of U.S. vaccine trials, the study reported. Mayur Murali, a researcher at Imperial College London, found similar trends in a 2023 paper studying British vaccine take-up. Asian volunteers made up 5.8% of all the COVID-19 vaccine trials analyzed and 1% of Black people were included despite these populations having higher mortality rates than white people, according to official data. Fear and mistrust of the health system contributed to their exclusion from the trials, said Murali. "With COVID-19 vaccine hesitancy for example, there was a lot of mistrust amongst ethnic minority communities and a lot of it was to do with misinformation and feeling locked out." According to a 2024 survey of over 8,000 people by research group Ipsos, 41% of ethnic minorities were willing to volunteer in a trial compared to 61% of white respondents, citing fear of side effects and mistrust of pharmaceutical companies. "If you can make that process transparent. ... I think people would be very happy to be involved," Murali said. With the United States turning its back on diversity initiatives, researchers hope Britain and Europe will step up. "I'm worried that the U.S. is not talking about equity, diversity and inclusion anymore," said Sonia Anand, a professor of medicine and epidemiology at McMaster University in Canada. "I really hope that these other governments will continue along the path to promoting the importance of equitable inclusion into clinical trials." There are promising signs. The World Health Organization last year released global guidance to improve diversity in trials. In Europe, a consortium of 73 private and public organizations launched Research in Europe and Diversity Inclusion (READI) in January to tackle the under-representation. British drugmaker GSK, which is part of READI, said the demand to conduct trials that are representative of the different populations and countries they work in remained high. Pfizer and Moderna, makers of COVID-19 vaccines, said they were committed to boosting diversity in clinical trials. In January, Britain began consulting on how best to reflect diverse ethnicity, age, sex and gender in clinical research. Naho Yamazaki, who is spearheading the draft guidance at Britain's Health Research Authority, said it was crucial the guidance truly removes barriers and was not just a "tick box" exercise. "Reducing health disparity requires far more than just equitable representation in clinical research. It's got to be a global effort ultimately. It's not a quick thing, but the momentum is here," Yamazaki said.
Yahoo
29-01-2025
- Health
- Yahoo
Kennedy says he will finalize rules that increase diversity in clinical trials
By Julie Steenhuysen CHICAGO (Reuters) - Robert F. Kennedy Jr., President Donald Trump's pick to lead the top U.S. health agency, told U.S. senators during his confirmation hearing on Wednesday that he would finalize regulations aimed at increasing the participation of diverse patient populations in clinical trials. The comment followed a purge last Friday of draft guidance and other diversity-related information from the U.S. Food and Drug Administration's website. Kennedy is nominated to run the U.S. Department of Health and Human Services, which oversees FDA. See for yourself — The Yodel is the go-to source for daily news, entertainment and feel-good stories. By signing up, you agree to our Terms and Privacy Policy. Asked by Democratic Senator Ben Ray Lujan whether he would commit to finalizing the guidance on clinical trial diversity mandated by Congress, Kennedy replied, "Yes." The FDA's Diversity Action Plan draft guidance to drugmakers and medical device companies fulfills a requirement laid out in the 2022 Food and Drug Omnibus Reform Act. Historically, most available evidence from clinical trials is based largely on white patients and may not account for differences in how drugs and devices work, or what side effects they may cause, in various patient populations. The law aims to increase participation of underrepresented groups, including Black and Hispanic Americans. The guidance would require drug and device makers to set goals and detail their strategies for enrolling people from diverse populations for every late-stage clinical trial of medicines and medical devices slated for U.S. regulatory review. The guidance was due to be finalized by June 2025, and it is not clear why it was removed from the FDA website. HHS and FDA spokespeople declined to comment, citing a communications moratorium imposed by the Trump administration until Feb. 1.
Reuters
29-01-2025
- Health
- Reuters
Kennedy says he will finalize rules that increase diversity in clinical trials
CHICAGO, Jan 29 (Reuters) - Robert F. Kennedy Jr., President Donald Trump's pick to lead the top U.S. health agency, told U.S. senators during his confirmation hearing on Wednesday that he would finalize regulations aimed at increasing the participation of diverse patient populations in clinical trials. The comment followed a purge last Friday of draft guidance and other diversity-related information from the U.S. Food and Drug Administration's website. Kennedy is nominated to run the U.S. Department of Health and Human Services, which oversees FDA. Asked by Democratic Senator Ben Ray Lujan whether he would commit to finalizing the guidance on clinical trial diversity mandated by Congress, Kennedy replied, "Yes." The FDA's Diversity Action Plan draft guidance to drugmakers and medical device companies fulfills a requirement laid out in the 2022 Food and Drug Omnibus Reform Act. Historically, most available evidence from clinical trials is based largely on white patients and may not account for differences in how drugs and devices work, or what side effects they may cause, in various patient populations. The law aims to increase participation of underrepresented groups, including Black and Hispanic Americans. The guidance would require drug and device makers to set goals and detail their strategies for enrolling people from diverse populations for every late-stage clinical trial of medicines and medical devices slated for U.S. regulatory review. The guidance was due to be finalized by June 2025, and it is not clear why it was removed from the FDA website. HHS and FDA spokespeople declined to comment, citing a communications moratorium imposed by the Trump administration until Feb. 1.
